C-myc Represses Transiently Transfected HLA Class I Promoter Sequences Not Locus-specifically
Overview
Affiliations
Overexpression of the c-myc oncogene is frequently accompanied by downregulation of Major Histocompatibility Complex (MHC, HLA in humans) class I antigens. In human melanoma c-myc overexpression downmodulates HLA-B expression, whereas HLA-A is hardly affected. Repression of HLA-B is mediated through the core promoter, containing a CAAT-box and a non-conventional TATA-box. We show evidence that in transient transfection assays the HLA-A2 and HLA-B7 promoters are repressed by c-myc to the same extent. Therefore, other sequences of the HLA-A and HLA-B genes, possibly intron/exon sequences, should contribute to the locus B-specificity of the downregulation. Furthermore, c-myc does not seem to alter binding of protein complexes to the CAAT- or TATA-box of HLA-B7 or HLA-A2 in gel retardation assays. Comparison of promoters repressed by c-myc reveals a weak consensus sequence of the initiator (Inr) element: TCA(+1)YYYNY. The presence of a TCA sequence in the initiator region of the MHC class I promoter makes downregulation by c-myc through the Inr likely. We speculate that the Inr contributes to MHC class I promoter activity by stimulating recruitment of TFIID to the weak, non-conventional TATA-box, thereby making it susceptible to repression by c-myc through the Inr.
HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy.
Maggs L, Sadagopan A, Moghaddam A, Ferrone S Trends Cancer. 2021; 7(12):1089-1101.
PMID: 34489208 PMC: 8651070. DOI: 10.1016/j.trecan.2021.07.006.
The MYC oncogene is a global regulator of the immune response.
Casey S, Baylot V, Felsher D Blood. 2018; 131(18):2007-2015.
PMID: 29514782 PMC: 5934797. DOI: 10.1182/blood-2017-11-742577.
Novel insights into the molecular mechanisms of HLA class I abnormalities.
Seliger B Cancer Immunol Immunother. 2011; 61(2):249-254.
PMID: 22120755 PMC: 11029063. DOI: 10.1007/s00262-011-1153-9.
Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma.
Maruyama T, Mimura K, Sato E, Watanabe M, Mizukami Y, Kawaguchi Y Br J Cancer. 2010; 103(4):552-9.
PMID: 20628381 PMC: 2939777. DOI: 10.1038/sj.bjc.6605772.